Executive Vice President, International Markets Commercial · TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Gianfranco Nazzi

FY2019 is the first fiscal year CompBrief holds for Gianfranco Nazzi as a named executive officer of TEVA PHARMACEUTICAL INDUSTRIES; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$3,449,172

Salary $541,580Stock awards $1,299,977Bonus $40,579

6th of 7 named executive officers at Teva Pharmaceutical Industries by FY2019 total.

7 named officers on file for TEVA PHARMACEUTICAL INDUSTRIES, FY2019

Gianfranco Nazzi’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • TEVA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TEVA PHARMACEUTICAL INDUSTRIES’s whole pay program stands against its peers

  • TEVA PHARMACEUTICAL INDUSTRIES’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TEVA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2020 (DEF 14A).

Free

Get Gianfranco Nazzi’s full pay file as a PDF — free

More than this page: up to 10 years of Gianfranco’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Gianfranco Nazzi compensation by year

TEVA PHARMACEUTICAL INDUSTRIES Summary Compensation Table · the one fiscal year held
In US dollars, as TEVA PHARMACEUTICAL INDUSTRIES reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$541,580
Bonus$40,579
Stock awards$1,299,977
Option awards$0
Non-equity incentive$552,505
Pension and deferred compensation$0
All other$1,014,531
Total$3,449,172

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TEVA PHARMACEUTICAL INDUSTRIES LTD DEF 14A filed April 22, 2020, accession 0001193125-20-114316, and prior-year filings. Open the filing on EDGAR.

How this page was built: the TEVA PHARMACEUTICAL INDUSTRIES LTD filed document, accession 0001193125-20-114316. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
PSU43,103$422,409—
PSU39,800$390,040—
RSU38,805$380,289—
RSU35,823$351,065—
RSU2,799$27,430—
RSU874$8,565—
Option4,628—$53.50
Option15,001—$34.70
Option91,326—$18.61

Per the Outstanding Equity Awards at Fiscal Year-End table in TEVA PHARMACEUTICAL INDUSTRIES LTD's FY2019 proxy; value at the fiscal year-end close, as the company printed it.

TEVA PHARMACEUTICAL INDUSTRIES’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Kåre SchultzPresident and Chief Executive Officer$11,596,564
Hafrun FridriksdottirExecutive Vice President, Global Research and Development$4,377,725
Carlo de NotaristefaniFormer Executive Vice President, Global Operations$4,318,838
Michael McClellanFormer Executive Vice President, Chief Financial Officer$4,231,243
Brendan O'GradyExecutive Vice President, North America Commercial$3,462,290
Gianfranco Nazzi · this pageExecutive Vice President, International Markets Commercial$3,449,172
Eli KalifExecutive Vice President, Chief Financial Officer$20,555

The full TEVA PHARMACEUTICAL INDUSTRIES compensation record

free company brief

This page is one person within TEVA PHARMACEUTICAL INDUSTRIES's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the TEVA PHARMACEUTICAL INDUSTRIES proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TEVA PHARMACEUTICAL INDUSTRIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Gianfranco Nazzi's compensation dossier · One-time report. No refunds.